Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Denali Therapeutics Inc DNLI

Healthcare Biotechnology
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease... see more

Current News (NDAQ:DNLI)

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

GlobeNewswire 11 days ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

GlobeNewswire December 30, 2025

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire December 10, 2025

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire December 9, 2025

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

GlobeNewswire December 4, 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

GlobeNewswire December 4, 2025

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire November 6, 2025

Denali Therapeutics Announces Board and Executive Leadership Updates

GlobeNewswire November 6, 2025

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

GlobeNewswire October 13, 2025
View More News ››

Opinion & Analysis (NDAQ:DNLI)

Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics

Streetwise Reports July 3, 2019
View More Opinion ››

Bullboard Posts (NDAQ:DNLI)

Don't forget to buy buy buy or you will be sorry.

Explosion coming soon. Everything is lining up 
Allearsbye - April 10, 2019

DNLI Run fast hmmm, timeline ?

It has potential to go 5x 
Allearsbye - March 28, 2019

This stock is going to run

This stock is going to run fast be ready
Allearsbye - March 12, 2019
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts